

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with Rituximab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.
2. The method of claim 1, wherein said liposome comprises sphingomyelin and cholesterol.
3. The method of claim 2, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol% sphingomyelin/mol% cholesterol) and 50/50 (mol% sphingomyelin/mol% cholesterol).
4. The method of claim 3, wherein the ratio of sphingomyelin to cholesterol is 55/45 (mol% sphingomyelin/mol% cholesterol).
5. The method of claim 1, wherein said vincristine is administered at a dosage of between 1.4 - 2.4 mg/m².
6. The method of claim 1, wherein said lymphoma is non-Hodgkin's lymphoma.
7. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (131I) Lym-1, wherein said relapsed

cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.

8. The method of claim 7, wherein said liposome comprises sphingomyelin and cholesterol.

9. The method of claim 8, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol% sphingomyelin/mol% cholesterol) and 50/50 (mol% sphingomyelin/mol% cholesterol).

10. The method of claim 7, wherein said lymphoma is non-Hodgkin's lymphoma.

11. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (¹³¹I) tositumomab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.

12. The method of claim 11, wherein said liposome comprises sphingomyelin and cholesterol.

13. The method of claim 12, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol% sphingomyelin/mol% cholesterol) and 50/50 (mol% sphingomyelin/mol% cholesterol).

14. The method of claim 11, wherein said lymphoma is non-Hodgkin's lymphoma.